Ticker
$COYA
1 catalyst touching COYA in the last 60 days, newest first, each with the price move that followed.
- 72
Coya Therapeutics completes Phase 2/3 enrollment for COYA 302 ALS trial
Coya announced full enrollment of 120 patients in the ALSTARS Phase 2/3 trial for COYA 302 in ALS treatment, with topline data expected in early Q2 2027. Enrollment completion is a concrete milestone that validates trial execution and moves the company closer to potential regulatory decision, reducing operational risk for an early-stage therapeutic company.
COYA ▲SEC 8-K · 5 Oct 2026, 12:30 UTC
Information only. AURA does not give buy or sell recommendations.